Gyre Therapeutics, Inc. GYRE Gyre — Fair Value Adjustment Of Warrants
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FairValueAdjustmentOfWarrants.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s gyre — fair value adjustment of warrants.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s gyre — fair value adjustment of warrants?
- Gyre Therapeutics, Inc. (GYRE) reported gyre — fair value adjustment of warrants of -$89K in Q1 2026.
- How has Gyre Therapeutics, Inc.'s gyre — fair value adjustment of warrants changed year-over-year?
- Gyre Therapeutics, Inc.'s gyre — fair value adjustment of warrants increased by 96.1% year-over-year, from -$2.26M to -$89K.
- What is the long-term trend for Gyre Therapeutics, Inc.'s gyre — fair value adjustment of warrants?
- Over 2 years (2023 to 2025), Gyre Therapeutics, Inc.'s gyre — fair value adjustment of warrants has grown at a -45.9% compound annual growth rate (CAGR), from $9.26M to -$2.71M.
- What does gyre — fair value adjustment of warrants mean?
- This reflects the periodic change in the estimated market value of outstanding warrants issued by the company. Because these are often classified as financial liabilities, fluctuations in the company's stock price can lead to significant non-cash gains or losses. This metric is essential for understanding volatility in net income that is not related to core business operations.